Due Diligence Manager
Martin joined AstraZeneca in April 2018 as a Due Diligence Director within the Business Development Operations team, based in Cambridge. BDO is a stand-alone business unit that pursues a range of business development opportunities that have a strategic fit with AZ’s portfolio and commercial capabilities, ranging from alliances and acquisitions in AZ’s main therapy areas, to externalisation activities. BDO works across the full deal life-cycle, from partner networking, due diligence, negotiations and deal-making, to the subsequent alliance and integration management of partnerships. Martin’s principal role is to manage due diligence for buy- and sell-side deals undertaken by BDO.
Prior to joining AZ, Martin spent 13 years at GlaxoSmithKline, latterly as a Science & Technology Licensing Director within GSK’s Worldwide Business Development function. Martin gained broad BD and deal team experience at GSK, and led due diligence for over 20 in-licensing opportunities from pre-clinical to late-clinical development stage, including for the licensing of MOR-103 (MorphoSys, anti-GM-CSF mAb, phase 2). On the sell-side, Martin led diligences for key divestments including the license of ofatumumab (anti-CD20 mAb, phase 3) to Novartis for MS and autoimmune indications.